09:23 AM EDT, 09/30/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Monday it submitted a supplemental biologics license application to the US Food and Drug Administration for pediatric growth hormone deficiency drug TransCon hGH, now targeting adults with growth hormone deficiency.

The submission is based on data from a phase 3 trial, the company said. The treatment was generally safe and well tolerated and no discontinuations were reported related to the study drug, it added.

Price: 144.50, Change: -0.12, Percent Change: -0.08